Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
With a new Democratic majority in Congress, healthcare fraud enforcement is poised to intensify — and the targets are getting more specific. From Medicare Advantage insurers and private equity-backed hospitals to pharmacy benefit managers and drug pricing, lawmakers and the DOJ are zeroing in on how the industry is organized, owned, and paid. For healthcare companies, exposure can arrive well before any agency formally acts.
A new Democratic majority in Congress is expected to sharpen the lens on healthcare fraud, building on a bipartisan foundation that has long viewed Medicare and Medicaid integrity as a political win for both parties. Former DOJ fraud chief Kevin Lowell argues the shift isn't about whether scrutiny continues — it's about where it lands next.
The DOJ's 2026 National Health Care Fraud Takedown set a record, charging 455 defendants in schemes totaling $6.5 billion in alleged losses, with CMS revoking billing privileges for over 2,400 providers. A newly created National Fraud Enforcement Division has since named healthcare fraud its top corporate enforcement priority. Congressional oversight is expected to complement — and amplify — that effort, with committee chairs empowered to subpoena documents, compel executive testimony, and refer matters directly to the DOJ.
By the Numbers:
Why it matters: Congressional hearings, subpoenas, and published staff reports can surface internal records and trigger whistleblower activity long before a formal investigation concludes — making proactive compliance a business imperative, not just a legal one.
